Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells

Hyun Chang; Hei Cheul Jeung; Je Jun Jung; Tae Soo Kim; Sun Young Rha; Hyun Cheol Chung

doi:10.1007/s10549-010-0825-z

Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells

Hyun Chang, Hei Cheul Jeung, Je Jun Jung, Tae Soo Kim, Sun Young Rha, Hyun Cheol Chung

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

44 Citations (Scopus)

Abstract

Here we evaluated the cytotoxic effects of a combination of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and taxanes in human breast cancer cell lines. Combination treatment with taxane and SAHA had a synergistic cytotoxic effect against taxane-resistant breast cancer cells. Oligonucleotide microarray analysis identified 28 genes (MAPK13, ATP2C1, ANKRD57, MT1G, RGL4, C12orf49, EXOC6, RAB4A, TM9SF3, IFNGR1, DMD, HCG9, KIFC3, SYNGR3, NDRG4, NT5E, EOMES, SMC4, LANCL1, SCHIP1, and 8 ESTs) whose expression correlated with the combined effect of paclitaxel and SAHA. Twelve of these genes were down-regulated in cell lines that were paclitaxel-resistant but combination synergistic. SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell. Our results indicate that a combination of taxane and SAHA could be efficacious for the treatment of breast cancer and that genes involved in the synergistic response to paclitaxel and SAHA could serve as biomarkers to predict therapeutic response in breast cancer patients.

Original language	English
Pages (from-to)	55-63
Number of pages	9
Journal	Breast Cancer Research and Treatment
Volume	125
Issue number	1
DOIs	https://doi.org/10.1007/s10549-010-0825-z
Publication status	Published - 2011 Jan

Bibliographical note

Funding Information:
Acknowledgments This work was supported by the Korea Science and Engineering Foundation (KOSEF) Grant funded by the Korea government (MOST) (R11-2000-082-03002-0 and R11-2000-082-02008-0).

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-010-0825-z

Cite this

@article{b86cf49771b343fea1c34bb1235d1078,

title = "Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells",

abstract = "Here we evaluated the cytotoxic effects of a combination of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and taxanes in human breast cancer cell lines. Combination treatment with taxane and SAHA had a synergistic cytotoxic effect against taxane-resistant breast cancer cells. Oligonucleotide microarray analysis identified 28 genes (MAPK13, ATP2C1, ANKRD57, MT1G, RGL4, C12orf49, EXOC6, RAB4A, TM9SF3, IFNGR1, DMD, HCG9, KIFC3, SYNGR3, NDRG4, NT5E, EOMES, SMC4, LANCL1, SCHIP1, and 8 ESTs) whose expression correlated with the combined effect of paclitaxel and SAHA. Twelve of these genes were down-regulated in cell lines that were paclitaxel-resistant but combination synergistic. SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell. Our results indicate that a combination of taxane and SAHA could be efficacious for the treatment of breast cancer and that genes involved in the synergistic response to paclitaxel and SAHA could serve as biomarkers to predict therapeutic response in breast cancer patients.",

author = "Hyun Chang and Jeung, {Hei Cheul} and Jung, {Je Jun} and Kim, {Tae Soo} and Rha, {Sun Young} and Chung, {Hyun Cheol}",

note = "Funding Information: Acknowledgments This work was supported by the Korea Science and Engineering Foundation (KOSEF) Grant funded by the Korea government (MOST) (R11-2000-082-03002-0 and R11-2000-082-02008-0).",

year = "2011",

month = jan,

doi = "10.1007/s10549-010-0825-z",

language = "English",

volume = "125",

pages = "55--63",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells

AU - Chang, Hyun

AU - Jeung, Hei Cheul

AU - Jung, Je Jun

AU - Kim, Tae Soo

AU - Rha, Sun Young

AU - Chung, Hyun Cheol

N1 - Funding Information: Acknowledgments This work was supported by the Korea Science and Engineering Foundation (KOSEF) Grant funded by the Korea government (MOST) (R11-2000-082-03002-0 and R11-2000-082-02008-0).

PY - 2011/1

Y1 - 2011/1

N2 - Here we evaluated the cytotoxic effects of a combination of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and taxanes in human breast cancer cell lines. Combination treatment with taxane and SAHA had a synergistic cytotoxic effect against taxane-resistant breast cancer cells. Oligonucleotide microarray analysis identified 28 genes (MAPK13, ATP2C1, ANKRD57, MT1G, RGL4, C12orf49, EXOC6, RAB4A, TM9SF3, IFNGR1, DMD, HCG9, KIFC3, SYNGR3, NDRG4, NT5E, EOMES, SMC4, LANCL1, SCHIP1, and 8 ESTs) whose expression correlated with the combined effect of paclitaxel and SAHA. Twelve of these genes were down-regulated in cell lines that were paclitaxel-resistant but combination synergistic. SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell. Our results indicate that a combination of taxane and SAHA could be efficacious for the treatment of breast cancer and that genes involved in the synergistic response to paclitaxel and SAHA could serve as biomarkers to predict therapeutic response in breast cancer patients.

AB - Here we evaluated the cytotoxic effects of a combination of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and taxanes in human breast cancer cell lines. Combination treatment with taxane and SAHA had a synergistic cytotoxic effect against taxane-resistant breast cancer cells. Oligonucleotide microarray analysis identified 28 genes (MAPK13, ATP2C1, ANKRD57, MT1G, RGL4, C12orf49, EXOC6, RAB4A, TM9SF3, IFNGR1, DMD, HCG9, KIFC3, SYNGR3, NDRG4, NT5E, EOMES, SMC4, LANCL1, SCHIP1, and 8 ESTs) whose expression correlated with the combined effect of paclitaxel and SAHA. Twelve of these genes were down-regulated in cell lines that were paclitaxel-resistant but combination synergistic. SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell. Our results indicate that a combination of taxane and SAHA could be efficacious for the treatment of breast cancer and that genes involved in the synergistic response to paclitaxel and SAHA could serve as biomarkers to predict therapeutic response in breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=78651086480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651086480&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-0825-z

DO - 10.1007/s10549-010-0825-z

M3 - Article

C2 - 20224928

AN - SCOPUS:78651086480

SN - 0167-6806

VL - 125

SP - 55

EP - 63

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this